[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613766":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":55,"collaborators":58,"id":61,"slug":10,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":10,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":72,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Fudan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A (Retrospective)",null,"A retrospective cohort of cases diagnosed between 2010 and 2024, assembled from medical-record data.\n\nTarget enrollment: 1,300-1,500 patients.",[13],"Other: Observational",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort B (Prospective)","A prospective cohort of patients newly diagnosed between 2025 and 2030, ensuring ≥5-year follow-up for all survivors.\n\nTarget sample size: 1,000-1,500 cases, estimated from participating centers' annual diagnostic volumes over a 5-year accrual period. The cohort should be multidimensionally representative, including: (i) geographic coverage across North, East, South, Southwest, and Northeast China; (ii) hospital tiers with tertiary (\"Class III Grade A\") institutions as the core and selective inclusion of prefecture-level hospitals; and (iii) economic diversity spanning regions with differing levels of socioeconomic development.",[13],[19],{"type":6,"name":20,"description":20,"armGroupLabels":21,"otherNames":10},"Observational",[9,15],[23],{"name":24,"affiliation":5,"role":25},"Rong Tao, MD","STUDY_CHAIR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","008621-64175590","660103","hkutao@hotmail.com",{"name":33,"role":28,"phone":29,"phoneExt":30,"email":34},"Chuanxu Liu, MD","liuchaunxu@shca.or.cn",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","201200","China",{"type":44,"coordinates":45},"Point",[46,47],121.45806,31.22222,{"lat":47,"lon":46},[50,52,53],{"name":24,"role":28,"phone":51,"phoneExt":10,"email":31},"021-64175590",{"name":33,"role":28,"phone":51,"phoneExt":10,"email":34},{"name":33,"role":54,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Rong Tao","Professor & Chief",[59],{"name":60,"class":6},"The First Affiliated Hospital of Zhengzhou University","100613766",false,"NCT07270861","Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study","A Multicenter, Non-interventional, Two-cohort Study to Describe Real-world Treatment Patterns and Outcomes in Patients With Peripheral T-cell Lymphoma","Inclusion Criteria:\n\n* Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms).\n* Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024.\n* Cohort B: Patients newly diagnosed from October 2025 onward.\n* Availability of basic diagnostic and treatment records .\n\nExclusion Criteria:\n\n* Indeterminate diagnosis or missing pathology report.\n* Patients diagnosed at an outside institution who did not receive their primary treatment and follow-up at a participating center.\n* Diagnoses of NK\u002FT-cell lymphoma or primary cutaneous T-cell lymphomas.","ALL","18 Years",{"count":70,"type":71},3000,"ESTIMATED","5 Years","OBSERVATIONAL","This study aims to characterize the epidemiology, clinicopathologic features, and survival outcomes of Chinese patients with PTCL; to develop and validate prognostic models to this population; to compare the real-world effectiveness and safety of alternative therapeutic strategies; to elucidate molecular mechanisms underlying treatment resistance and relapse; to identify actionable targets and predictive biomarkers.",[76],"Peripheral T-Cell Lymphoma",[78,79,80,81,82],"T-cell lymphoma","Retrospective cohort","Prospective cohort","Epidemiology","Biomarkers","2026-03-20",{"date":85,"type":86},"2026-03-24","ACTUAL",{"date":88,"type":86},"2025-11-15",{"date":90,"type":71},"2035-12-31",{"name":5,"class":6},1]